Tranexamic acid, an antifibrinolytic agent recently used to treat melasma in Asian patients, improves rosacea by reducing IL-6, TNFα, and MMP expression, and also lowers the angiogenesis of rosacea by reducing VEGF expression and the number of CD31+ cells [103]. The gene discussed is PECAM1; the disease is rosacea.